Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.43 |
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | JAK1 | P23458 | 4/20 | 0.35 |
| ▸ | JAK3 | P52333 | 5/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25808704 | 0.81 | IDO1 (0.41) | IDO1TDO2JAK1JAK3TBXAS1 | |
| SCHEMBL14738333 | 0.76 | IDO1 (0.38) | IDO1TDO2SRC | |
| SCHEMBL25976858 | 0.72 | HSP90AA1 (0.36) | IDO1TDO2SRC | |
| SCHEMBL23065942 | 0.68 | TBXAS1 (0.57) | IDO1TDO2SRCTBXAS1TNKS | |
| SCHEMBL24924432 | 0.66 | TBXAS1 (0.36) | IDO1TDO2JAK1JAK3TBXAS1 | |
| SCHEMBL23869923 | 0.64 | TNKS (0.49) | IDO1TDO2TNKSTNKS2 | |
| SCHEMBL22230306 | 0.62 | IDO1 (0.36) | IDO1TDO2SRC | |
| SCHEMBL25822555 | 0.61 | SRC (0.35) | IDO1TDO2SRCTNKSTNKS2 | |
| SCHEMBL22792808 | 0.60 | TBXAS1 (0.32) | IDO1TDO2TBXAS1TNKSTNKS2 | |
| SCHEMBL22792575 | 0.60 | IDO1 (0.39) | IDO1TDO2SRCTBXAS1TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | IDO1 906/4885TDO2 933/4885JAK1 2140/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | IDO1 906/4885TDO2 933/4885JAK1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.